The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Birchbiomed’s FS2 (kynurenic acid) for the treatment of idiopathic pulmonary fibrosis (IPF). Orphan drug status is ...
VANCOUVER, BC, Dec. 2, 2025 /PRNewswire/ - BirchBioMed Inc., a leading clinical stage biopharmaceutical company, expert in the development of products for scarring and other fibrosis-related disorders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback